A safety and feasibility trial of 131 I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study-Reference-Cited by-同舟云学术

A safety and feasibility trial of 131 I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study

Published:2021-05-24 Issue:10 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Weiss Brian D.¹^ORCID,Yanik Gregory²,Naranjo Arlene³,Zhang Fan F.⁴^ORCID,Fitzgerald Wendy⁵,Shulkin Barry L.⁶^ORCID,Parisi Marguerite T.⁷,Russell Heidi⁸^ORCID,Grupp Stephan⁹,Pater Luke¹,Mattei Peter⁹,Mosse Yael⁹,Lai Hollie A.¹⁰,Jarzembowski Jason A.¹¹,Shimada Hiroyuki¹²,Villablanca Judith G.¹³^ORCID,Giller Roger¹⁴,Bagatell Rochelle⁹,Park Julie R.¹⁵,Matthay Katherine K.¹⁶^ORCID

Affiliation:

1. Cincinnati Children's Hospital University of Cincinnati School of Medicine Cincinnati Ohio

2. CS Mott Children's Hospital University of Michigan School of Medicine Ann Arbor Michigan

3. Children's Oncology Group Statistics and Data Center University of Florida Gainesville Florida

4. Children's Oncology Group Statistics and Data Center Monrovia California

5. Children's National Health System District of Columbia Washington

6. St. Jude Children's Research Hospital University of Tennessee Health Science Center Memphis Tennessee

7. Seattle Children's Hospital Seattle Washington

8. Texas Children's Cancer and Hematology Centers Center for Medical Ethics and Health Policy Baylor College of Medicine Houston Texas

9. Children's Hospital of Philadelphia Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania

10. Children's Hospital of Orange County Orange California

11. Midwest Children's Cancer Center Milwaukee Wisconsin

12. Lucille Packards Children's Hospital Palo Alto California

13. Children's Hospital Los Angeles Keck School of Medicine University of Southern California Los Angeles California

14. Children's Hospital Colorado University of Colorado School of Medicine Aurora Colorado

15. Seattle Children's Hospital University of Washington School of Medicine Seattle Washington

16. UCSF Benioff Children's Hospital University of California San Francisco School of Medicine San Francisco California

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29117

Reference37 articles.

1. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

2. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)

3. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

4. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

5. Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field;Radiotherapy and Oncology;2024-09

2. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma;Cancers;2024-08-17

3. Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols;Transplantation and Cellular Therapy;2024-07

4. A Randomised Phase II Trial to Evaluate the Feasibility of Radiotherapy Dose Escalation, Facilitated by Intensity-Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma;Clinical Oncology;2024-06

5. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma;EJC Paediatric Oncology;2024-06